Is Abbott Laboratories (ABT) 10% Leap a Good Sign for Investors?

Plenty of stocks are making headlines in the absolute chaos of the DeepSeek launch. If that kind of volatility doesn’t interest you, we’ve got a stock that might be up your alley: Abbott Laboratories (NYSE: ABT).

ABT has enjoyed a period of strong performance due to continued strong demand for its tests and products, growth in Q4 2024, and growing sales of its glucose monitoring systems.

1-month chart, courtesy TradingView 

Currently, analysts are raising targets on ABT. Why? One reason is that healthcare is important to consumers even in slightly more turbulent and unknown economic times, and ABT’s product offerings allow it to place itself in front of people with common medical needs (glucose monitors, respiratory tests, etc.). This is just one of the reasons why ABT could be a “safer” investment option right now.

The consensus of analysts we follow on WallStreetZen agrees, with a consensus rating of… “Buy” among 15 analysts. While the 12-month average price forecast for ABT is only +2.24 percent, you may want to keep watching — analysts might have updated their targets yet in light of recent news. The maximum forecast is also more favorable at +22.07%.

A message from our sponsors...

Here's precisely how to capitalize on a booming copper market in 2025

Copper is booming with copper stocks setting up to be this year's big winner. Particularly the small-caps with high-grade projects in safe mining jurisdictions. This small-cap mining firm has around a billion pounds of copper already confirmed in mining-friendly Canada. It doesn't get any safer than that. Plus, shares are currently trading undiscovered around 10-cents.

Don't miss the free report.

Thanks to our sponsors for keeping this content free.

Additionally, it’s rated a “B” using our Zen Ratings system. This is significant because our rating system isn’t ruled by the news cycles — investor sentiment is only a portion of the 115 factors it takes into account to issue ratings. As a B-rated stock, ABT has demonstrated excellence in a variety of areas. 

Since our Zen Rating grades are based on 7 different Component Grades, let’s take a closer look at ABT’s areas of strength. 

ABT currently has an “A” rating in Safety, indicating a stable business that’s great for more conservative investors. It also has its financials in order and is currently a good value according to our model.

To recap, here are a few reasons to consider keeping ABT on watch:  

• It has a Zen Rating of B, indicating it is in the top 20% of stocks we cover. Stocks with a Zen Rating of B had an average return of +19.88% per year. Notably, it scored an A in “Safety,” indicating it is a better pick for more conservative investors.
• Optimism is high for many of its products, especially medical devices related to diabetes.
• While it may not be the strongest growth stock on the market right now, it can be a safer, more conservative pick amid uncertain economic times and crises in the more growth-focused tech sector.

However, only you will know what options are best for your portfolio. Nonetheless, we can help. You need ideas, information, and a way to keep track of important updates. WallStreetZen Premium offers all three, giving you access to analyst insights, all the fundamental information you need, and an unlimited watchlist that will let you stay on top of stocks like ABT and others. 

What to Do Next?

• Watch “Zen Ratings Revolution” to Unlock +32.52% Annual Gains >
• Upgrade Your Investing - Start Your Premium Trial Now! >
• Discover Zen Investor portfolio to Find More 100%+ Stock Winners>

Want to get in touch? Email us at news@wallstreetzen.com.